首页>
外国专利>
COMBINED THERAPY WITH TYPE II ANTI-CD20 ANTIBODIES IN COMBINATION WITH ANTI-BCL-2 ACTIVE AGENT
COMBINED THERAPY WITH TYPE II ANTI-CD20 ANTIBODIES IN COMBINATION WITH ANTI-BCL-2 ACTIVE AGENT
展开▼
机译:结合II型抗CD20抗体与抗BCL-2活性剂联合治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: medicine, pharmaceutics.;SUBSTANCE: group of inventions refers to a combination of a type II anti-CD20 antibody and an anti-Bcl-2 active agent for treating cancer, first, CD20 expressing cancer, wherein the above type II anti-CD20 antibody is a humanised B-Lyl antibody and the above active agent is a Bcl-2 protein binding inhibitor and thereby destroys the Bad/Bcl-2 complex with the IC50 anti-Bcl-2 inhibitory activity of 1 mcM or less, as well as to using the type II anti-CD20 antibody for producing a medical drug applicable for treating cancer, first, CD20 expressing cancer, in a combination with the anti-Bcl-2 active agent.;EFFECT: group of inventions in effective in treating cancer, first, CD20 expressing cancer, in a combination with the anti-Bcl-2 active agent.;10 cl, 3 dwg, 2 tbl, 4 ex
展开▼